Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study was designed to assess the safety and efficacy of multiple interferon-free
treatment regimens of sofosbuvir (Sovaldi™; GS-7977; PSI-7977) and GS-0938 (PSI-352938) alone
and in combination, with and without ribavirin (RBV). Each regimen was to be evaluated over
12 and 24 weeks to identify the optimal duration of therapy to maximize the benefit
(sustained virologic response [SVR]) versus risk (safety and resistance).